Aramco Ventures (Wa’ed Ventures)

Wa’ed Ventures is the corporate venture arm of Saudi Aramco, headquartered in Dhahran and operating as the Kingdom’s most strategically important early-stage and growth-stage technology investor. The fund manages a $500M vehicle with a publicly committed $100M dedicated allocation for AI investments announced in late 2024, and as of late 2025 has invested approximately $270M into more than 75 companies, by some counts now closer to 93 portfolio companies after recent deployments, with eleven new investments in the trailing twelve months. Wa’ed’s positioning as a corporate VC rather than a pure financial fund is critical context: it operates with a Vision 2030 mandate, is staffed by Aramco-aligned investment professionals, and structures its portfolio choices around the Kingdom’s broader objective of becoming a regional and global hub for AI, energy transition, and digital infrastructure. The AI advisory board explicitly includes academic and policy figures alongside operating entrepreneurs, which signals that the fund’s diligence weighs national-strategy fit alongside commercial venture returns; in practice, portfolio companies that align cleanly with Saudi industrial policy and localization priorities receive meaningful tailwinds, while companies that do not can find themselves competing for partner attention with more strategically-aligned peers. For healthcare founders, the most concrete portfolio reference point is Athir, the Saudi-based healthcare information system company founded in 2017 by Jawad Chaudhry, Ahmad AlJehani, and Abdoulmohsen Alyoubi, which raised its first investment round backed by Wa’ed alongside SHARE Investment Co. and RZM Investment in 2024. Athir’s product spans hospital management, revenue cycle, medical insurance integration, and patient-facing applications providing integrated medical records for clinic and medical centre visitors, a full-stack healthcare IT play designed for Saudi clinic and hospital workflows, and it represents the archetype of localized deep-tech infrastructure that Wa’ed prioritizes in healthcare. Beyond Athir, Wa’ed’s healthtech exposure sits inside a broader portfolio covering AI, IoT, fintech, e-commerce, drones, cloud and supercomputing, agtech, edtech, and energy and industrial applications, with the recurring through-line that portfolio companies should either be Saudi-founded or willing to localize meaningfully into the Kingdom. The fund has been operating since 2013, which gives it more than a decade of relationship continuity with Saudi government buyers, MoH digitization initiatives, and the Saudi Data and AI Authority, relationships that translate directly into procurement access for portfolio companies that can execute. Stage and check sizing of $5M to $25M with explicit appetite from Pre-Seed through growth makes Wa’ed unusually flexible for a corporate VC, and the fund will lead, co-lead, or follow depending on the round dynamics; the AI fund within the broader vehicle has loosened structural rigidity that traditionally constrains corporate VCs to strategic-alignment investments. Co-investment with STV, PIF-affiliated funds, and select international VCs is common, and the strategic introductions a Wa’ed check can unlock (Aramco itself as a customer or supplier-ecosystem partner, Ministry of Health digitization initiatives, NEOM-aligned procurement, Saudi insurance reform tenders under the CCHI framework) are often more valuable than the capital itself. Founders who fit are operators building healthcare IT and revenue cycle infrastructure for Saudi and GCC providers, AI applied to Arabic-language clinical workflows and documentation, occupational and industrial health platforms that align with Aramco’s own operational footprint and supplier base, digital therapeutics targeting the Kingdom’s chronic disease and Vision 2030 wellness priorities (diabetes, obesity, cardiovascular disease, mental health), and deep-tech founders willing to relocate or establish a Riyadh or Dhahran operating presence that goes beyond a token regional office. Founders who do not fit include US or European healthcare companies looking for a passive Saudi strategic without localization commitment, pure therapeutics and biotech teams (out of scope), consumer wellness brands without an enterprise or institutional wedge, and seed-stage teams without a clear thesis on how their wedge interacts with Saudi industrial policy or Aramco’s own value chain. The intro path is through Wa’ed directly via the Aramco entrepreneurship channel and the Wa’ed website application process, through STV or PIF-affiliated co-investors who frequently syndicate with Wa’ed, via a Saudi government relationship in MoH, SDAIA, or MCIT, or through Aramco’s industrial supplier ecosystem if the wedge is occupational health or industrial-adjacent. In the pitch, lead with a credible Saudi localization plan including timelines and headcount commitments, demonstrate alignment with specific Vision 2030 healthcare KPIs, articulate how Aramco itself or its supplier ecosystem could be a customer or strategic partner, and bring Arabic-language product depth where applicable; vague Vision 2030 alignment language without operational specificity is a recognized failure mode. The caveats: Wa’ed is a corporate VC with the institutional pace and governance expectations that implies, the fund’s strategic priorities can shift with Aramco’s broader agenda and energy-transition imperatives, founders who do not commit to a meaningful Kingdom presence will under-extract from the relationship and may find diligence and approvals slower than at a comparable independent VC, and the corporate-VC structure means that competing strategic priorities within Aramco can occasionally compress portfolio companies’ optionality on partnerships and acquisitions in ways purely financial investors would not impose.